CARVEDILOL: A BETA BLOCKER OF CHOICE FOR THE TREATMENT OF PATIENTS WITH REYNAUD'S PHENOMENON AND CARDIOVASCULAR DISEASES

  • Milovan M Stojanović 1. Institute for treatment and rehabilitation Niška Banja, Deparatment for cardiovascular diseases, Niš, Serbia; 2. University of Niš, Faculty of medicine, Serbia
  • Jovan Nedovic Institute for treatment and rehabilitation Niška Banja, Clinic for rheumatology, Niš, Serbia
  • Stevan Ilić Clinic for Cardiovascular Diseases Cardio Point, Niš, Serbia
DOI: https://doi.org/10.5937/sanamed0-52781
Keywords: n/a

Abstract


n/a

References

Nawaz I, Nawaz Y, Nawaz E, Manan MR, Mahmood A. Raynaud's phenomenon: reviewing the pathophysiology and management strategies. Cureus. 2022;14(1):e21681. doi: 10.7759/cureus.21681.

Devgire V, Hughes M. Raynaud's phenomenon. Br J Hosp Med (Lond). 2019;80(11):658-64. doi: 10.12968/hmed.2019.80.11.658.

England BR, Thiele GM, Anderson DR, Mikuls TR. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ. 2018;361:k1036. doi: 10.1136/bmj.k1036.

Cannarile F, Valentini V, Mirabelli G, Alunno A, Terenzi R, Luccioli F et al. Cardiovascular disease in systemic sclerosis. Ann Transl Med. 2015;3(1):8. doi: 10.3978/j.issn.2305-5839.2014.12.12.

Jha SB, Rivera AP, Flores Monar GV, Islam H, Puttagunta SM, Islam R, et al. Systemic Lupus Erythematosus and cardiovascular disease. Cureus. 2022;14(2):e22027. doi: 10.7759/cureus.22027.

Porsch F, Binder CJ. Autoimmune diseases and atherosclerotic cardiovascular disease. Nat Rev Cardiol. 2024 Jun 27. doi: 10.1038/s41569-024-01045-7. Epub ahead of print.

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. doi: 10.1093/eurheartj/ehab368.

Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415-537. doi: 10.1093/eurheartj/ehae177.

McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024:ehae178. doi: 10.1093/eurheartj/ehae178. Epub ahead of print.

Herrick AL. Raynaud's phenomenon. J Scleroderma Relat Disord. 2019;4(2):89-101. doi: 10.1177/2397198319826467.

Mohokum M, Hartmann P, Schlattmann P. The association of Raynaud syndrome with β-blockers: a meta-analysis. Angiology. 2012;63(7):535-40. doi: 10.1177/0003319711432861.

Koraćević G, Stojanović M, Kostić T, Lović D, Zdravković M, Koraćević M, et al. Contraindications differ widely among beta blockers and ought to be cited for an individual drug, Not for the entire class. Curr Pharm Des. 2021;27(40):4125-32. doi: 10.2174/1381612827666210716162130.

Koracevic G, Micic S, Stojanovic M, Lovic D, Simic D, Colic M, et al. Compelling indications should be listed for individual beta-blockers (due to diversity), not for the whole class. Curr Vasc Pharmacol. 2021;19(4):343-6. doi: 10.2174/1570161118666200518113833.

Eliasson K, Danielson M, Hylander B, Lindblad LE. Raynaud's phenomenon caused by beta-receptor blocking drugs. Improvement after treatment with a combined alpha- and beta-blocker. Acta Med Scand. 1984;215(4):333-9.

Abdullah A, Yusof MKM. Labetalol: a brief current review. Pharmacophore. 2019:10(6-2019):50-6.

Beattie K, Phadke G, Novakovic J. Carvedilol. Profiles Drug Subst Excip Relat Methodol. 2013;38:113-57. doi: 10.1016/B978-0-12-407691-4.00004-6.

Singh S, Preuss CV. Carvedilol. [Updated 2023 Mar 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534868/

Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al.; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106(17):2194-9. doi: 10.1161/01.cir.0000035653.72855.bf.

Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266):1385-90. doi: 10.1016/s0140-6736(00)04560-8.

Published
2024/10/09
Issue
Sanamed online first-accepted articles
Section
Letter to editor

Copyright (c) 2024 Sanamed

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Journal Sanamed is published under an Open Access license. All its content is available free of charge. Users can read, download, copy, distribute, print, search the full text of articles, as well as establish HTML links to them, without having to seek the consent of the author or publisher.

The right to use content without consent does not release the users from the obligation to give the credit to the journal and its content in a manner described under CC BY.